Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Bipolar Disorder Treatment Market –Insights

Bipolar disorder, also known as manic illness, is a brain disorder that affects the mood, energy level, and other activities. This disorder consists of various episodes, and major among these are – manic and depression. There is a sudden change in mood of the patient and his/her ability to carry out daily tasks. There are four types of bipolar disorders: bipolar I, bipolar II, cyclothymic, and other specified and non-specified bipolar and related disorders.

The people suffering from bipolar disorder experience periods of unusually intense emotion, irregular sleep patterns and activity levels, and mood episodes. Bipolar disorder is diagnosed based on the patient’s symptoms, family history, and lifetime history. The healthcare provider generally conducts a mental health evaluation for the diagnosis of bipolar disorder. 

The global bipolar disorder treatment market size is estimated to be valued at US$ 7,288.3 million in 2019 and is expected to exhibit a CAGR of 5.2% over the forecast period (2019-2027).

Figure 1. Global Bipolar Disorder Treatment Market Value (US$ Mn), by Region, 2019

Bipolar Disorders Treatment  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2020)

Increasing product approvals and launches are expected to propel the market growth over the forecast period

Key players are focusing on enhancing their product portfolio through increasing launches and approvals of new drugs for the treatment of bipolar disorder, which is expected to drive growth of the bipolar disorder treatment market over the forecast period. For instance, in May 2019, Allergan plc and Gedeon Richter Plc. received the U.S. Food and Drug Administration (FDA) approval for its supplemental new drug application (sNDA) of VRAYLAR (cariprazine), anoral, once daily atypical antipsychotic drug for expanded use and treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults.

Moreover, in May 2016, Procera Health announced the launch of ProceraMood, a non-prescription drug, which offers mood stabilization, and supporting balance and calmness.

Figure 2. Global Bipolar Disorder Treatment Market Share (%), by Drug Class, 2019 and 2027

Bipolar Disorders Treatment  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2020)

Increasing mergers, agreements, and collaborations to develop treatment for bipolar disorder is expected to drive the market growth over the forecast period

Market players are focused on adoption of inorganic growth strategies such as collaborations and partnerships to strengthen their position in the bipolar disorder treatment market. For instance, in November 2017, Sumitomo Dainippon Pharma Co., Ltd and Angelini S.p.A entered into a strategic partnership in order to distribute and commercialize Latuda (Lurasidone Hydrochloride), developed by Sumitomo Dainippon Pharma, in the European market (29 European countries and in Turkey). Under this agreement, a subsidiary company of Sumitomo Dainippon Pharma Group (Sunovion Pharmaceuticals Europe Ltd.) granted rights to Angelini for distribution and commercialization of LATUDA in European Market.

However, side effects associated with drugs used in the treatment of bipolar disorder is expected to be a factor negatively affecting growth of the market up to certain extent, as patients hesitate to undergo medication therapy due to fear of the same. For instance, some of the medications including carbamazepine, Divalproex sodium, and Lithium used in the treatment of bipolar disorder have some side effects such as nausea, tremors, sexual problem, impaired memory, muscle weakness, decreased thyroid function, liver and kidney damage, skin reactions, and others.

Key Players

Major players operating in the global bipolar disorder treatment market include Takeda Pharmaceutical Company Limited, Pfizer, Inc., Allergan plc, Otsuka Holdings Co. Ltd., Johnson & Johnson, Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca Plc, Novartis International AG, AbbVie Inc., H. Lundbeck A/S, Minerva Neurosciences, Sumitomo Dainippon Pharma Co., Ltd., Intra-Cellular Therapies Inc., Gedeon Richter Plc., and Indivior PLC.

Bipolar disorder is a lifelong disease, which can be managed with proper medication. The medications used to manage bipolar disorder symptoms include mood stabilizers and atypical antipsychotics. Mood stabilizers such as lithium and other drugs are used for the treatment of bipolar disorders by suppressing mood swings such as mania and depression. Cariprazine is an atypical antipsychotic drug indicated for the treatment of depressive episodes associated with bipolar I disorder in adults. Antidepressant medications are also prescribed to treat depressive episodes in bipolar disorder. Antidepressants combined with mood stabilizers are indicated to prevent triggering of maniac episode in patients with bipolar disorder.

Market Dynamics

The increasing adoption of inorganic growth strategies such as mergers, agreements, and collaborations by key players operating in the market are expected to propel the market growth over the forecast period. For instance, in July 2019, Gedeon Richter plc, entered into an exclusive license agreement with Hikma Pharmaceuticals Plc. to commercialize cariprazine, a novel antipsychotic drug, in certain Middle East and North African or MENA markets. Moreover, earlier in August 2016, Gedeon RichterPlc. and Recordati signed an exclusive license agreement to commercialize cariprazine, a novel atypical antipsychotic drug in Western Europe, Algeria, and Tunisia.

Key features of the study:

  • This report provides in-depth analysis of the global bipolar disorder treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2019–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global bipolar disorder treatment market based on the following parameters – company overview, financial performance, Device portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Takeda Pharmaceutical Company Limited, Pfizer, Inc., Allergan plc, Otsuka Holdings Co. Ltd., Johnson & Johnson, Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca Plc, Novartis International AG, AbbVie Inc., H. Lundbeck A/S, Minerva Neurosciences, Sumitomo Dainippon Pharma Co., Ltd., Intra-Cellular Therapies Inc., Gedeon Richter Plc., and Indivior PLC
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future device launches, drug class up-gradation, market expansion, and marketing tactics
  • The global bipolar disorder treatment market report caters to various stakeholders in this industry including investors, suppliers, device manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bipolar disorder treatment market

Detailed Segmentation:

  • Global Bipolar Disorder Treatment Market, By Drug Class:
    • Antipsychotics
    • Antidepressants
    • Mood Stabilizers
    • Anti-anxiety Drugs and Others
  • Global Bipolar Disorder Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Bipolar Disorder Treatment Market, By Region:
    • North America
      • By Drug Class:
        • Antipsychotics
        • Antidepressants
        • Mood Stabilizers
        • Anti-anxiety Drugs and Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drug Class:
        • Antipsychotics
        • Antidepressants
        • Mood Stabilizers
        • Anti-anxiety Drugs and Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Class:
        • Antipsychotics
        • Antidepressants
        • Mood Stabilizers
        • Anti-anxiety Drugs and Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class:
        • Antipsychotics
        • Antidepressants
        • Mood Stabilizers
        • Anti-anxiety Drugs and Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Class:
        • Antipsychotics
        • Antidepressants
        • Mood Stabilizers
        • Anti-anxiety Drugs and Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class:
        • Antipsychotics
        • Antidepressants
        • Mood Stabilizers
        • Anti-anxiety Drugs and Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Takeda Pharmaceutical Company Limited*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Pfizer, Inc.
    • Allergan plc
    • Otsuka Holdings Co. Ltd.
    • Johnson & Johnson
    • Eli Lilly and Company
    • GlaxoSmithKline plc
    • AstraZeneca Plc
    • Novartis International AG
    • AbbVie Inc.
    • Lundbeck A/S
    • Minerva Neurosciences
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Intra-Cellular Therapies Inc.
    • Gedeon Richter Plc.
    • Indivior PLC

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • PEST Analysis
  4. Global Bipolar Disorder Treatment Market, By Drug Class, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Antipsychotics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Antidepressants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Mood Stabilizers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Anti-anxiety Drugs and Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  5. Global Bipolar Disorder Treatment Market, By Distribution Channel, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Bipolar Disorder Treatment Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  7. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Takeda Pharmaceutical Company Limited
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer, Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Allergan plc
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Otsuka Holdings Co. Ltd.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Johnson & Johnson
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Eli Lilly and Company
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GlaxoSmithKline plc
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • AstraZeneca Plc
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novartis International AG
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • AbbVie Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Lundbeck A/S
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Minerva Neurosciences
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sumitomo Dainippon Pharma Co., Ltd.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Intra-Cellular Therapies Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Gedeon Richter Plc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Indivior PLC
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
        • Analyst Views
  8. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 27 market data tables and 26 figures on "Bipolar Disorder Treatment Market” - Global forecast to 2027.

Frequently Asked Questions

This report provides in-depth analysis of the global bipolar disorder treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2019 – 2027). The report also provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
Key segments covered in the report include: • Drug Class • Distribution Channel • Region
The report provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
The increasing healthcare expenditure, increasing number of drug approvals for the treatment of bipolar disorder, adoption of inorganic growth strategies by key players, and increasing prevalence of bipolar disorders are the drivers for this market.
The report profiles leading players in the global bipolar disorder treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and future plans.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner